HDAC9 and B-cell non-Hodgkin lymphoma: HDAC inhibitors exhibit antitumor activity for multiple myeloma (Song et al., 2011; Santo et al., 2012) and B cell lymphoma (Cortiguera et al., 2019) by suppressing cells survival and differentiation and inducing apoptosis.